Short answer
Denali Therapeutics Inc. (DNLI) filed an 8-K current report with the SEC on May 22, 2026 reporting Item 7.01 (Regulation FD Disclosure). Phase 2b LUMA topline results for BIIB122 (DNL151) in early-stage Parkinson’s disease.
Denali Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Phase 2b LUMA topline results for BIIB122 (DNL151) in early-stage Parkinson’s disease
- Results announced jointly with Biogen on May 21, 2026
- Clinical readout potentially material for Denali’s Parkinson’s pipeline and Biogen collaboration
- Full efficacy and safety details in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Denali Therapeutics Inc. 8-K filings
Get the next DNLI 8-K as it lands
Follow DNLI for push alerts, or ask the research agent what this filing means.